Principles of Adoptive T Cell Cancer Therapy

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2007 May 4

PMID 17476350

Citations 122

Authors

Carl H June

Affiliations

Soon will be listed here.

Abstract

The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.

Citing Articles

Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on "Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular....

Bertoletti A, Tan A Clin Mol Hepatol. 2024; 30(4):728-734.

PMID: 38934109 PMC: 11540402. DOI: 10.3350/cmh.2024.0469.

Biomaterial-enhanced treg cell immunotherapy: A promising approach for transplant medicine and autoimmune disease treatment.

Mashayekhi K, Khazaie K, Faubion Jr W, Kim G Bioact Mater. 2024; 37:269-298.

PMID: 38694761 PMC: 11061617. DOI: 10.1016/j.bioactmat.2024.03.030.

Cell therapy biomanufacturing: integrating biomaterial and flow-based membrane technologies for production of engineered T-cells.

Bomb K, LeValley P, Woodward I, Cassel S, Sutherland B, Bhattacharjee A Adv Mater Technol. 2023; 8(6).

PMID: 37600966 PMC: 10437131. DOI: 10.1002/admt.202201155.

Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy.

Shin S, Lee P, Han J, Kim S, Lim J, Park D Tissue Eng Regen Med. 2023; 20(3):371-387.

PMID: 36867402 PMC: 9983528. DOI: 10.1007/s13770-022-00515-8.

PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy.

Zhang D, Li A, Hu G, Huang M, Yang F, Zhang L Cell Metab. 2023; 35(3):517-534.e8.

PMID: 36804058 PMC: 10088869. DOI: 10.1016/j.cmet.2023.01.010.

References

Blansfield J, Beck K, Tran K, Yang J, Hughes M, Kammula U . Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005; 28(6):593-8. PMC: 2154350. DOI: 10.1097/01.cji.0000178913.41256.06. View

Harrington L, Hatton R, Mangan P, Turner H, Murphy T, Murphy K . Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005; 6(11):1123-32. DOI: 10.1038/ni1254. View

Schmitz-Winnenthal F, Volk C, Zgraggen K, Galindo L, Nummer D, Ziouta Y . High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res. 2005; 65(21):10079-87. DOI: 10.1158/0008-5472.CAN-05-1098. View

Rapoport A, Stadtmauer E, Aqui N, Badros A, Cotte J, Chrisley L . Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005; 11(11):1230-7. DOI: 10.1038/nm1310. View

Fritsch R, Shen X, Sims G, Hathcock K, Hodes R, Lipsky P . Stepwise differentiation of CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol. 2005; 175(10):6489-97. DOI: 10.4049/jimmunol.175.10.6489. View

Zhou J, Shen X, Huang J, Hodes R, Rosenberg S, Robbins P . Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005; 175(10):7046-52. PMC: 1351312. DOI: 10.4049/jimmunol.175.10.7046. View

Zhang Y, Joe G, Hexner E, Zhu J, Emerson S . Host-reactive CD8+ memory stem cells in graft-versus-host disease. Nat Med. 2005; 11(12):1299-305. DOI: 10.1038/nm1326. View

Horikawa I, Chiang Y, Patterson T, Feigenbaum L, Leem S, Michishita E . Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element. Proc Natl Acad Sci U S A. 2005; 102(51):18437-42. PMC: 1317953. DOI: 10.1073/pnas.0508964102. View

McKenzie B, Kastelein R, Cua D . Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 2005; 27(1):17-23. DOI: 10.1016/j.it.2005.10.003. View

10.

Hirano N, Butler M, Xia Z, Ansen S, von Bergwelt-Baildon M, Neuberg D . Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2005; 107(4):1528-36. PMC: 1895397. DOI: 10.1182/blood-2005-05-2073. View

11.

Porter D, Levine B, Bunin N, Stadtmauer E, Luger S, Goldstein S . A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood. 2005; 107(4):1325-31. DOI: 10.1182/blood-2005-08-3373. View

12.

June C, Blazar B . Clinical application of expanded CD4+25+ cells. Semin Immunol. 2006; 18(2):78-88. DOI: 10.1016/j.smim.2006.01.006. View

13.

Weng N . Aging of the immune system: how much can the adaptive immune system adapt?. Immunity. 2006; 24(5):495-9. PMC: 2266981. DOI: 10.1016/j.immuni.2006.05.001. View

14.

Langowski J, Zhang X, Wu L, Mattson J, Chen T, Smith K . IL-23 promotes tumour incidence and growth. Nature. 2006; 442(7101):461-5. DOI: 10.1038/nature04808. View

15.

Suntharalingam G, Perry M, Ward S, Brett S, Castello-Cortes A, Brunner M . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006; 355(10):1018-28. DOI: 10.1056/NEJMoa063842. View

16.

Wallace D, Berard M, Soares M, Oldham J, Cook J, Akbar A . Prolonged exposure of naïve CD8+ T cells to interleukin-7 or interleukin-15 stimulates proliferation without differentiation or loss of telomere length. Immunology. 2006; 119(2):243-53. PMC: 1782358. DOI: 10.1111/j.1365-2567.2006.02429.x. View

17.

Janzen V, Forkert R, Fleming H, Saito Y, Waring M, Dombkowski D . Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006; 443(7110):421-6. DOI: 10.1038/nature05159. View

18.

Blackburn E, Greider C, Szostak J . Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med. 2006; 12(10):1133-8. DOI: 10.1038/nm1006-1133. View

19.

Fowler D, Odom J, Steinberg S, Chow C, Foley J, Kogan Y . Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006; 12(11):1150-60. DOI: 10.1016/j.bbmt.2006.06.015. View

20.

Xin Z, Beauchamp A, Calado R, Bradford J, Regal J, Shenoy A . Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood. 2006; 109(2):524-32. DOI: 10.1182/blood-2006-07-035089. View